Is Cytokinetics Inc. (CYTK) Positioned for Success With Its Innovative Muscle Modulators?
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $90
Buy Rating Affirmed for Cytokinetics Following Promising Aficamten Clinical Trial Results
Cytokinetics New Analysis of Heart Medication Study Shows Beneficial Changes
Cytokinetics Presents Additional Data From SEQUOIA-HCM At The HCMS Scientific Sessions; Says "Overall, 83.8% Of Patients Treated With Aficamten Experienced Favorable Effects In At Least One Of The Five Domains, Compared To 39.3% Of Patients On Placebo"
Express News | Cytokinetics Presents Additional Data From Sequoia-HCM at the Hcms Scientific Sessions